Literature DB >> 26850361

Chronic hepatitis B and fatty liver: Issues in clinical management.

Rajneesh Kumar1, George Boon-Bee Goh2.   

Abstract

With an increasing incidence of non-alcoholic fatty livers, the existence of concomitant hepatitis B and fatty liver is becoming more common in clinical practice. In clinical practice, the concomitant existence of hepatitis B and fatty livers raises practical issues in clinical management. It becomes more difficult for the clinician to decide on the mode of treatment in the case of elevated Alanine aminotransferase (ALT) and in deciding potential causes, whether they are related to chronic hepatitis B or to non-alcoholic steatohepatitis (NASH). With evolving changes in the practice and knowledge of non-alcoholic fatty liver disease and chronic hepatitis B, clinical judgment on the predominant disease becomes essential for their coexistence. This short review is aimed at reviewing the evidence available on the frequency of the two diseases existing concomitantly, possible ways of differentiating the two, the prognosis, outcomes of treatment and a possible common pathway. Copyright Â
© 2016. Published by Elsevier Masson SAS.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 26850361     DOI: 10.1016/j.clinre.2015.12.011

Source DB:  PubMed          Journal:  Clin Res Hepatol Gastroenterol        ISSN: 2210-7401            Impact factor:   2.947


  6 in total

Review 1.  HBsAg Loss as a Treatment Endpoint for Chronic HBV Infection: HBV Cure.

Authors:  Maryam Moini; Scott Fung
Journal:  Viruses       Date:  2022-03-22       Impact factor: 5.818

2.  The gamma-glutamyl transpeptidase to platelet ratio for non-invasive assessment of liver fibrosis in patients with chronic hepatitis B and non-alcoholic fatty liver disease.

Authors:  Qiang Li; Chuan Lu; Weixia Li; Yuxian Huang; Liang Chen
Journal:  Oncotarget       Date:  2017-04-25

3.  A Noninvasive Score Model for Prediction of NASH in Patients with Chronic Hepatitis B and Nonalcoholic Fatty Liver Disease.

Authors:  Jing Liang; Fang Liu; Fengmei Wang; Tao Han; Li Jing; Zhe Ma; Yingtang Gao
Journal:  Biomed Res Int       Date:  2017-03-02       Impact factor: 3.411

4.  Interface Hepatitis over Grade 2 May Differentiate Chronic Inflammation Associated with CHB from NAFLD in the Early Stage.

Authors:  Yong-Fen Zhu; Jin Wang; Jia-Zhui Fang; Qiao Yang; Fang-Fang Lv
Journal:  Gastroenterol Res Pract       Date:  2020-04-20       Impact factor: 2.260

5.  Presence of Hepatic Steatosis Does Not Increase the Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Over Long Follow-Up.

Authors:  Chong Teik Lim; George Boon Bee Goh; Huihua Li; Tony Kiat-Hon Lim; Wei Qiang Leow; Wei Keat Wan; Rafay Azhar; Wan Cheng Chow; Rajneesh Kumar
Journal:  Microbiol Insights       Date:  2020-05-13

6.  Hepatitis B virus infection is not associated with fatty liver disease: Evidence from a cohort study and functional analysis.

Authors:  Bingqian Wang; Wenna Li; Hezhi Fang; Huaibin Zhou
Journal:  Mol Med Rep       Date:  2018-11-02       Impact factor: 2.952

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.